As per the agreement, WuXi PharmaTech is expected to become a provider of toxicology and other non-clinical services to Janssen. In addition, Janssen will provide training and other services, reimbursed by WuXi, to establish the GLP quality system and technical capabilities to meet the international standards at WuXi’s toxicology facility in Suzhou, China.
The facility is currently conducting non-GLP toxicology services, as well as client-sponsored GLP validation studies to demonstrate its growing capabilities. WuXi PharmaTech said that it would remain on target to begin offering GLP toxicology studies by mid-2010.
Ge Li, chairman and CEO of WuXi PharmaTech, said: “We are pleased to establish this new partnership with Janssen, which builds on our existing agreement to provide them with integrated pharmaceutical R&D services.
“We believe that China, with its high-quality scientific talent and favorable cost structure, is destined to become a major center for toxicology services over the next decade.”